Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine

BACKGROUND: The metabolic inhibitor 3-bromopyruvate (3-BrPA) is a promising anti-cancer alkylating agent, shown to inhibit growth of some colorectal carcinoma with KRAS mutation. Recently, we demonstrated increased resistance to 3-BrPA in wt p53 tumor cells compared to those with p53 silencing or mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Orue, Andrea, Chavez, Valery, Strasberg-Rieber, Mary, Rieber, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116131/
https://www.ncbi.nlm.nih.gov/pubmed/27863474
http://dx.doi.org/10.1186/s12885-016-2930-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116131/
https://www.ncbi.nlm.nih.gov/pubmed/27863474
http://dx.doi.org/10.1186/s12885-016-2930-9

Ejemplares similares